A lack of confirmation with alternative assays questions the validity of IL-17A expression in human neutrophils using immunohistochemistry  by Tamarozzi, Francesca et al.
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 lack  of  conﬁrmation  with  alternative  assays  questions  the  validity  of
L-17A  expression  in  human  neutrophils  using  immunohistochemistry
rancesca  Tamarozzia,1,  Helen  L.  Wrightb, Huw  B.  Thomasb, Steven  W.  Edwardsb,
ark J.  Taylora,∗
Department of Parasitology, Liverpool School of Tropical Medicine, Liverpool, UK
Institute of Integrative Biology, University of Liverpool, Liverpool, UK
 r  t  i  c  l e  i  n  f  o
rticle history:
a  b  s  t  r  a  c  t
We  identiﬁed  IL-17A-positive  neutrophils  in Wolbachia-positive  Onchocerca  volvulus  nodules  using an
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antibody  that  has  previously  reported  IL-17A-positive  neutrophils  in  several  inﬂammatory  conditions.
However,  we  could  not  detect  IL-17A  using  a range  of  alternative  assays.  Our data  question  the  IL-17A
antibody  speciﬁcity  and  the  ability  of  human  neutrophils  to express  IL-17A.
©  2014  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
Interleukin-17 (IL-17) is an important mediator of inﬂamma-
ory and infectious disease [1] and the main source of IL-17 has,
ntil recently, been believed to be Th17 cells [2]. While a number
f recent reports have proposed that neutrophils are a source of
L-17 in inﬂammatory and infectious diseases in both mouse and
umans [3–20], the ability of human neutrophils to express IL-17A
s controversial [21].
The pathologic features of onchocerciasis mirror IL-17-
ediated immune responses. The combination of stimuli from the
larial nematode and its bacterial endosymbiont Wolbachia could
romote a cytokine milieu favourable for the induction of an IL-17-
ediated immune response [22], but little is currently known about
he actual presence and role of such a response in ﬁlariasis [23–25].
e identiﬁed IL-17A expressing neutrophils in Wolbachia-positive
nchocerca volvulus nodules from infected Cameroonian patients
26] using immunohistochemistry (IHC) staining with a commer-
ially available antibody (R&D Systems, goat polyclonal anti-IL-17A,
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nces, University of Pavia, Pavia, Italy.
ttp://dx.doi.org/10.1016/j.imlet.2014.10.025
165-2478/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unAF-317-NA) that has been used in other studies of IL-17A expres-
sion in neutrophils [4–13]. However, when we  tried to conﬁrm this
ﬁnding using alternative assays, we were unable to conﬁrm this
expression of IL-17 by human neutrophils.
2. Methods
2.1. Immunohistochemistry staining of O. volvulus nodules
Nodules from patients infected with O. volvulus were surgically
removed, ﬁxed in 80% ethanol and parafﬁn-embedded as part of the
evaluation of a phase II trial of doxycycline [26]. Sections of 4 m
were cut by microtome and mounted in an electrothermal bath at
45 ◦C on poly l-lysine slides (which were incubated overnight at
58 ◦C before use). After re-hydration and antigen retrieval (per-
formed in an 800 W microwave with two cycles of 3.5 min in
1 mM EDTA pH 8.0), endogenous peroxidase was  quenched by
incubation for 30 min in 3% H2O2 in methanol, before sections
were blocked for 30 min  in TNB blocking buffer. IHC staining was
carried out using the following antibodies: goat anti-human IL-
17A (1:10 or 1:50, AF-317-NA R&D Systems), mouse anti-human
CD4 (1:40, 1-F6 Novocastra), donkey anti-goat IgG-HRP conjugated
(1:500 or 1:1000, OB1500P AbD Serotec), goat anti-mouse IgG-
HRP conjugated (1:800, NEF822 Perkin Elmer). The tyramine signal
ampliﬁcation (TSA) (FITC or Cy3, Perkin Elmer) system was  used
to detect antibody bound to the target. Slides stained omitting
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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he primary antibody were included as a control for non-speciﬁc
inding of the secondary antibody. The use of normal goat IgG
n place of the primary antibody controlled for non-speciﬁc bind-
ng of the goat anti-human IL-17A IgG antibody. To conﬁrm total
uenching of endogenous peroxidase, TSA-Cy3 staining was  car-
ied out immediately after the H2O2 quenching step. No signal was
etected, conﬁrming that no endogenous peroxidase was  present.
API was used to stain nuclear DNA. H&E staining was  performed
sing standard techniques.
.2. Isolation of neutrophils and PBMCs
Participants gave informed consent according to the Declara-
ion of Helsinki. Ethics approval was obtained from the University
f Liverpool Committee on Research Ethics and Liverpool School
f Tropical Medicine Research Ethics Committee. Blood was  col-
ected into lithium-heparin vacutainers and separated into cellular
ractions using Polymorphprep (Axis-Shield). PBMCs were isolated
rom the upper band and neutrophils from the lower band, as
reviously described [27]. Neutrophil purity was  >97% and via-
ility was >98%. For some experiments (as indicated in Section
), neutrophils were separated from whole blood using the Easy-
ep Human Neutrophil Enrichment kit (Stem Cell), which provided
egatively selected (untouched) neutrophils with 99.9% purity.
eutrophils and PBMCs were incubated at 37 ◦C in a humidiﬁed
ncubator in RPMI 1640 (with 25 mM HEPES and 2 mM l-glutamine)
ulture media (Gibco). Neutrophils and/or PBMCs were incu-
ated for up to 15 h with synthetic WoLP (1 g/mL) (the primary
olbachia-derived pro-inﬂammatory molecule (EMC Microcollec-
ions) [28]), ultra-pure LPS (0.1 g/mL, Sigma), DMSO (Sigma),
r ﬁlarial extracts containing Wolbachia (BmFE, 200 g/mL) and
epleted from Wolbachia (BmFEtet, 200 g/mL). PBMCs were incu-
ated for up to 15 h with PMA  (50 ng/mL, Sigma)/ionomycin
10 g/mL, Sigma) to induce differentiation of CD4+/IL-17+ T-cells.
.3. Western blotting
Neutrophils and PBMCs were lysed in boiling Laemmli buffer.
rotein samples (106 cells) were separated by SDS-PAGE (12–14%
el) and transferred onto PVDF membrane (Millipore). Cul-
ure supernatant was precipitated in ice cold acetone (1:3 v/v)
vernight at −20 ◦C, followed by centrifugation at 900 × g for
 min. The pellet was lysed in 100 l boiling Laemmli buffer,
nd 30 l was loaded. Recombinant human IL-17A (R&D Sys-
ems) was used as a positive control (16.6 ng/lane). Antibodies
sed were goat anti-human IL-17A (AF-317-NA, R&D Systems,
:500 or 1:2500), mouse anti-human IL-17A (41802, R&D Sys-
ems, 1:500 or 1:5000), rabbit anti-human IL-17A (PRS4877,
igma, 1:500), goat anti-human IL-17A (sc-6077, Santa Cruz,
:100), HRP-conjugated donkey anti-goat IgG (OBT1500P, AbD
erotec, 1:5000), HRP-conjugated goat anti-mouse IgG (NEF822,
erkin Elmer, 1:5000), HRP-conjugated goat anti-mouse IgG/IgM
M30907, Caltag; 1:50,000), and HRP-conjugated mouse anti-goat
gG (31400, Thermo Scientiﬁc; 1:100,000). Bound antibodies were
etected using the ECL system (Millipore) or SuperSignal West
ura Extended Duration Substrate for HRP (Thermo Scientiﬁc) on
arefully-exposed ﬁlm (Amersham) to avoid saturation.
.4. Measurement of IL-17A by ELISA and Luminex
Levels of IL-17A in cell lysates and culture supernatants were
easured using two different ELISA kits (DuoSet ELISA Develop-
ent kit, R&D Systems; ELISA Ready-SET-Go! Kit, eBiosciences)
nd two different Luminex kits (Bio-Plex Pro Reagent kit, Bio-Rad;
illiplex MAG  Immunoassay kit, Millipore) as per the manufac-
urer’s instructions. Absorbance readings from the ELISA assaysetters 162 (2014) 194–198 195
were measured using a FLUOstar Omega plate reader, and Luminex
assays were analysed in a Bio-Plex system (Luminex xMAP tech-
nology). Minimum detection limits of IL-17A were 7.8 pg/mL for
ELISA and 3.2 pg/mL for Luminex.
2.5. Isolation of RNA and analysis by RNA-Seq and RT-PCR
RNA was isolated using TRIzol-chloroform (Invitrogen) as
previously described [27], and cleaned using an RNeasy mini
kit (Qiagen), including a DNA digestion step. RNA-Seq analysis
of neutrophil mRNA was  carried out on the Illumina plat-
form as previously described [27]. For RT-PCR, total RNA was
reverse transcribed into cDNA using SuperScript III ﬁrst strand
synthesis system, as per the manufacturer’s instructions. PCR
primers were: IL-17A forward 5′-ACTACAACCGATCCACCTCAC-
3′, reverse 5′-ACTTTGCCTCCCAGATCACAG-3′; ribosomal protein
S12 (housekeeping gene) forward 5′-GAATTCGCGAAGCTGCCAAA-
3′, reverse 5′-GACTCCTTGCCATAGTCCTT-3′. Ampliﬁcation was
performed with Quantitect SYBR Green PCR kit, as per the manu-
facturer’s instructions, using an annealing temperature of 55 ◦C and
40 cycles. PCR products were visualised on a 1% agarose gel. For the
sequencing of PCR products, bands were excised and DNA extracted
using QIAEX II gel extraction kit. Extracted DNA was sequenced
using a Beckman Coulter Genomics system (Essex, UK).
2.6. Immunoprecipitation and mass spectrometry
PMN  (5 × 106 in 1 mL)  and PBMC (1 × 106 in 200 L) were lysed
in Pierce IP Lysis Buffer (Thermo Scientiﬁc) as per the manufac-
turer’s instructions. Immunoprecipitation was  carried out using
100 g mouse anti-human IL-17A antibody (41802, R&D Sys-
tems) and 60 g goat anti-human IL-17A antibody (AF-317-NA,
R&D Systems) coupled to 1 mL  HiTrap NHS-activated HP columns
and AKTAprime Plus low-pressure afﬁnity chromatography system
(both from GE Healthcare) using the manufacturer’s protocol. Pro-
tein samples underwent chromatographic separation prior to mass
spectrometric analysis using an UntimateTM3000 system. Elec-
trospray ionisation tandem mass spectrometry (ESI-MSMS) was
performed using an LTQ Obritrap Velos mass spectrometer. MSMS
data were processed using Proteome Discoverer 1.1TM software and
searched against the non-redundant human database from Uniprot
using the MASCOT search engine.
3. Results
IHC staining of Onchocerca nodules indicated strong IL-17A sig-
nals in cells around the Wolbachia-containing worms (Fig. 1A). In
order to identify the cellular source of the IL-17A signal, we coun-
terstained the nodules for CD4 and found that only 5.16% of CD4+
T-cells were IL-17A+, but that the majority of IL-17A+ cells (>70%)
did not stain CD4+ (Fig. 1B). We  used sequential H&E staining of sec-
tions stained for IL-17A to identify the IL-17A+ cells as neutrophils
(Fig. 1C), and found that IL-17A+ neutrophils were localised within
Onchocerca nodules in close proximity to Wolbachia-containing
worms (Fig. 1D).
In order to further investigate IL-17A expression by human
neutrophils in response to Wolbachia,  we  carried out IHC on donor-
derived neutrophils following stimulation with WoLP. We found
that 0 h healthy control neutrophils stained positive for IL-17A
using this assay, and that expression of IL-17A was  upregulated by
stimulation with WoLP (Fig. 1E). In contrast, healthy control PBMCs
only stained for IL-17A when cells were differentiated into CD4+/IL-
17A+ Th17 cells (by stimulation with PMA/ionomycin, data not
shown). Staining was  independent of ethanol or formalin ﬁxation
(data not shown).
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Fig. 1. Detection of IL-17A in human neutrophils by IHC. (A) Cyanine3 labelled IL-17A+ cells inﬁltrate Wolbachia-containing nodules but not Wolbachia-depleted nodules. (B)
Counterstaining with FITC labelled CD4+ antibody revealed the IL-17A+ cells were not Th17 cells. (C) H&E staining identiﬁed the IL-17A+ cells as neutrophils. (D) Representative
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embrane is shown in green. (E) IHC of healthy control neutrophils at time 0 h or tr
eutrophils which were IL-17A+ (Cynanine3, red). (For interpretation of the referen
In order to investigate expression of IL-17A by neutrophils fur-
her, we carried out Western blot analysis of neutrophil lysates
ncubated for up to 12 h with WoLP, DMSO (WoLP vehicle con-
rol), LPS or in media alone (Fig. 2A). Western blotting using the
ame antibody used for IHC (AF-317-NA, R&D, goat) identiﬁed mul-
iple bands in all samples, but none of the bands corresponded to
he molecular weight of rh-IL-17A (lane 1, Fig. 2A). We therefore
epeated our analysis with a second IL-17A antibody (41802, R&D,
ig. 2. Determination of IL-17A expression by human neutrophils. (A) Western blotting
L-17A  antibody. Bands detected were not of the same molecular weight as rhIL-17A (lan
ut  did detect rhIL-17A (lane 1). Mouse anti-IL-17A antibody detected a band in all sam
olecular weight of rhIL-17A (lane 1). (C) ELISA analysis of neutrophil and PBMC cell lysa
MA/ionomycin (lysate and supernatant). (D) RT-PCR of PBMC mRNA detected IL-17A mR
o  IL-17A was detected in neutrophil mRNA. Four bands were excised and sequenced (deere stained for IL-17A (Cyanine3, red) and DNA (DAPI, blue). The Wolbachia worm
 for 4 h in the absence or presence of WoLP (1 g/mL) revealed a high proportion of
 color in this ﬁgure caption, the reader is referred to the web version of this article.)
mouse). Whilst this antibody only detected one band, the relative
mobility did not correspond to the molecular mass of rh-IL-17A
(Fig. 2A). We repeated our analysis using PBMCs incubated for up
to 12 h with PMA/ionomycin, WoLP, DMSO, LPS or media alone.
Western blotting using the IHC antibody (AF-317-NA, R&D, goat)
did not detect any bands in any PBMC lysates, but did detect IL-
17A in PMA/ionomycin PBMC culture supernatant (Fig. 2B). Only
when membranes were processed with long-exposure ECL, a band
 of neutrophil (PMN) cell lysate using goat anti-IL-17A antibody and mouse anti-
e 1). (B) Goat anti-IL-17A antibody did not detect any protein in PBMC cell lysate
ples (including HEK cell lysate, negative control), which did not correspond to the
te and supernatant only detected IL-17A in PBMC samples incubated for 12 h with
NA in PBMC treated for 1 h with PMA/ionomycin (lane 12). No band corresponding
tails in text).
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Table  1
Identiﬁcation of proteins precipitated from neutrophil cell lysate following incubation for 4 h with WoLP (1 g/mL) by goat anti-IL-17A and mouse anti-IL-17A antibodies
(both  R&D Systems).
IP antibody Uniprot accession Protein description Protein accession MASCOT score Coverage (%) No. of peptides
Goat-anti human
IL-17A
P05164-2 Myeloperoxidase Isoform H14 PERM HUMAN 556.76 12.00 9
A5A6M6 Keratin, type II cytoskeletal 1 K2C1 PANTR 431.18 16.64 8
H2Q7J2 Uncharacterised protein H2Q7J2 PANTR 402.60 16.43 7
P35908 Keratin, type II cytoskeletal 2 K22E HUMAN 329.34 11.11 6
B7Z4X2 Lactoferroxin-C B7Z4X2 HUMAN 301.00 9.01 4
H2QCX3 Uncharacterised protein H2QCX3 PANTR 222.35 6.41 3
B3KSI4 Uncharacterised protein B3KSI4 HUMAN 181.12 6.30 2
P07737 Proﬁlin-1 PROF1 HUMAN 171.92 28.57 3
F8VV32 Lysozyme C F8VV32 HUMAN 105.66 10.19 2
Mouse anti-human IL-17A P13645 Keratin, type I cytoskeletal 10 K1C10 HUMAN 918.76 35.95 15
P04264 Keratin, type II cytoskeletal 1 K2C1 HUMAN 880.01 27.95 16
P35908 Keratin, type II cytoskeletal 2 K22E HUMAN 771.04 24.41 12
P59666 Neutrophil defensin DEF3 HUMAN 702.51 19.15 2
P05164-2 Myeloperoxidase Isoform H14 PERM HUMAN 682.52 18.46 13
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pP20160 Azurocidin 
P35527 Keratin, type I cytoske
B2MUD5 Neutrophil elastase 
f the same size was detectable in PBMC samples (data not shown).
 second anti-IL-17A antibody (41802, R&D, mouse) detected a
and in all samples at the same molecular mass as was  detected
n neutrophil lysates. However, this did not have the same elec-
rophoretic mobility as rh-IL-17A, and was also detected in HEK
ell lysate which was used as a negative control (Fig. 2B). Two
urther anti-human IL-17A antibodies were tested (sc-6077, Santa
ruz; PRS4877, Sigma). The Santa Cruz antibody gave multiple non-
peciﬁc bands and the Sigma antibody gave results overlapping
ith the R&D (goat) antibody (data not shown).
We next measured IL-17A in cell lysates and culture super-
atants using two ELISA (R&D kit, and eBisocience kit) and two
uminex (Bio-Rad kit, and Millipore kit). Results were consistent
cross all four independent kits. IL-17A was only detected in lysate
nd supernatant from PMA/ionomycin differentiated PBMCs. No
L-17A was detected in neutrophil lysates or supernatants after
ncubation under several experimental conditions (up to 15 h stim-
lation with WoLP, LPS, BmFE, BmFEtet or DMSO). Importantly, the
apture antibody in the ELISA kit from R&D was the same antibody
hat gave a positive IHC result and a negative Western blot result
AF-317-NA, goat anti-human IL-17A). Representative data for the
Bioscience ELISA is shown in Fig. 2C.
Analysis of mRNA by RT-PCR was carried out on neutrophils,
BMCs, and neutrophils containing a 5% PBMC “spike” after incu-
ation for up to 4 h in the absence and presence of WoLP, DMSO,
r LPS, and in PBMCs incubated for 1 h with PMA/ionomycin.
garose gel analysis only identiﬁed a band of the correct size in
he PMA/ionomycin PBMC sample (Fig. 2D). Multiple bands were
etected in neutrophil samples. Four of these (labelled i–iv in gel)
ere excised from the gel and sequenced, and found to represent
ither [i] FAM50A gene (unrelated), [ii and iv] IL-17A, or [iii] primer
imers. The IL-17A bands in the neutrophil samples were the same
ntensity as in the 5% PBMC spiked sample, and it is likely that the
ontaminating PBMCs in the neutrophil samples are the source of
L-17.
Analysis of mRNA by RNA-Seq found no transcripts for IL-17A
RPKM = 0) in neutrophils from RA patients (n = 29), healthy con-
rols (n = 7) or healthy neutrophils treated for 1 h with a range
f inﬂammatory cytokines (TNF, GM-CSF, G-CSF, IL-6, IL-1, IL-8,
FN, IFN,  n ≥ 3). A comparison of neutrophils isolated by poly-
orphprep (97% pure) or negative-selection (>99.9% pure) also
ailed to identify any transcripts for IL-17A, or indeed any of the
L-17A-F cytokines (RPKM < 0.3).
Finally, we performed mass-spectrometry on cell-lysates
rom neutrophils stimulated for 4 h with WoLP and immuno-
recipitated with both R&D antibodies (goat, mouse). The resultsCAP7 HUMAN 355.82 21.91 5
K1C9 HUMAN 347.65 9.47 4
B2MUD5 HUMAN 124.32 9.38 2
are shown in Table 1. IL-17A was not detected in either sample,
while it was  correctly identiﬁed in the rh-IL-17A control sample.
4. Discussion
Our investigation identiﬁed IL-17A positive neutrophils in
Wolbachia-positive O. volvulus nodules from infected patients
using a commercially-available antibody which has previously
been used to identify IL-17A expression by neutrophils in other
published studies [4–13]. However, further investigation using a
comprehensive range of laboratory techniques failed to detect
transcription of IL-17A mRNA, or expression and/or secretion
of IL-17A protein by human neutrophils under different exper-
imental conditions. Furthermore, several commercially available
anti-human IL-17A antibodies were tested using Western blot-
ting of neutrophil and PBMC protein lysates and were shown
to detect non-speciﬁc bands that did not correspond to IL-17A.
Importantly, IP using the antibody that gave a positive result
for IHC failed to identify IL-17A in neutrophil cell lysates. This
antibody detected multiple non-speciﬁc bands in neutrophil cell
lysate by Western blot, and was the capture antibody in the R&D
ELISA kit, which also failed to detect IL-17A in neutrophil cell
lysates or culture supernatants. One possible way of testing the
antigen-speciﬁcity of an antibody is by pre-absorbing it with the
antigen and then assessing the negative staining of an antigen-
positive sample in IHC when the pre-absorbed antibody is used.
In the case of goat anti-human IL-17A (AF-317-NA, R&D Sys-
tems), this approach was  successful in the work of Appel et al.
[6], but in the experimental work presented here it resulted in
non-speciﬁc background staining in all conditions tested (data not
shown).
Since the completion of our experiments described here, Taylor
et al. [14] have reported IL-17A expression by murine and human
neutrophils. However, our experimental approach differed from
theirs in a number of important aspects. First, in our experiments,
Ct values from qPCR experiments in excess of 30 cycles generate
unreliable data, especially when using RNA extracted from neu-
trophil preparations that are contaminated with other leukocytes
or when the RNA extraction method fails to include a DNAse step.
We  consistently ﬁnd that qPCR experiments using neutrophil RNA
that has not included a DNAse step are inevitably contaminated
with DNA that contributes to qPCR reactions. Second, we  do not
use cytokines at such high concentrations (20 g/mL).
Our comprehensive study raises doubt over the ability of
human neutrophils to express IL-17A and we  suggest caution
should be taken when interpreting IHC analysis of IL-17A-positive
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eutrophils using commercially available antibodies in the absence
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